Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 1, 2016, Pages 101-108

  Watanabe, A ^a   Matsumoto, T ^b   Igari, H ^c   Sawa, J ^d   Yamaguchi, Y ^d   Sakatani, M ^e  

^a TOHOKU UNIVERSITY   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c SAKURA NATIONAL HOSPITAL   (Japan)

^d ABBVIE INC   (United States)

^e Seika Cho Hospital   (Japan)

Author keywords

Anti TNF therapy; Case control study; Pharmacovigilance; Postmarketing surveillance

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ISONIAZID; METHOTREXATE; PREDNISONE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ANOREXIA; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG EFFICACY; DRUG RESPONSE; EXTRAPULMONARY TUBERCULOSIS; FATIGUE; FEVER; INCIDENCE; INFECTION RISK; INTERSTITIAL PNEUMONIA; JAPAN; KIDNEY DISEASE; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PLEURA EFFUSION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SPUTUM; SYMPTOMATOLOGY; THORAX PAIN; TUBERCULOSIS; ADULT; AGE; AGED; ARTHRITIS, RHEUMATOID; COMPLICATION; FEMALE; HUMAN; MALE; MIDDLE AGED; POSTMARKETING SURVEILLANCE; TUBERCULOSIS, PULMONARY;

ADALIMUMAB; ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 84951927446     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.15.0283     Document Type: Article

References (26)

1. Public Health England. Tuberculosis in the UK: 2014 report. London, UK: Public Health England, 2014.
2. European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2014. Stockholm, Sweden: ECDC, 2014.
3. Aberra F N, Stettler N, Brensinger C, Lichtenstein G R, Lewis J D. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 2007; 5: 1070-1075.
4. Askling J, Fored C M, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-1992.
5. Seong S S, Choi C B, Woo J H, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34: 706-711.
6. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-722.
7. Aggarwal R, Manadan A M, Poliyedath A, Sequeira W, Block J A. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 2009; 36: 914-917.
8. Dixon W G, Hyrich K L, Watson K D, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-528.
9. Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti-TNF-alpha agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 2012; 32: 2675-2679.
10. O'Garra A, Redford P S, McNab F W, Bloom C I, Wilkinson R J, Berry M P. The immune response in tuberculosis. Annu Rev Immunol 2013; 31: 475-527.
11. Keane J, Gershon S, Wise R P, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
12. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
13. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-1132.
14. Gómez-Reino J J, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761.
15. Schiff M H, Burmester G R, Kent J D, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-894.
16. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010; 6: 644-652.
17. Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol 2014; 24: 390-398.
18. Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3000 patients. Mod Rheumatol 2012; 22: 498-508.
19. Maeda T, Banno S, Maeda S, et al. Comparison of QuantiFERON-TB Gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients. J Infect Chemother 2011; 17: 842-848.
20. Tsuyuguchi K, Matsumoto T. Biologics and mycobacterial diseases. Kekkaku 2013; 88: 337-353. [Japanese]
21. Zevallos M, Justman J E. Tuberculosis in the elderly. Clin Geriatr Med 2003: 19: 121-138.
22. Lalvani A, Millington K A. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008; 8: 147-152.
23. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49: 1-51.
24. Greenberg J D, Reed G, Kremer J M, et al. CORRONA Investigators. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69: 380-386.
25. Bongartz T, Sutton A J, Sweeting M J, Buchan I, Matteson E L, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
26. Singh J A, Christensen R, Wells G A, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009; 181: 787-796.